Kiora Pharmaceuticals Analyst Ratings
Kiora Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/13/2023 | 483.33% | HC Wainwright & Co. | → $3.5 | Reiterates | Buy → Buy |
| 11/06/2023 | 483.33% | HC Wainwright & Co. | $2 → $3.5 | Maintains | Buy |
| 08/24/2023 | 233.33% | HC Wainwright & Co. | → $2 | Reiterates | Buy → Buy |
| 08/14/2023 | 233.33% | HC Wainwright & Co. | $7 → $2 | Maintains | Buy |
| 08/09/2023 | 233.33% | Maxim Group | $12 → $2 | Maintains | Buy |
| 05/12/2023 | 1066.67% | HC Wainwright & Co. | $6 → $7 | Maintains | Buy |
| 03/24/2023 | 900% | HC Wainwright & Co. | $10 → $6 | Reiterates | → Buy |
| 02/09/2023 | 1900% | Maxim Group | → $12 | Upgrades | Hold → Buy |
| 02/08/2023 | 1566.67% | HC Wainwright & Co. | → $10 | Reiterates | → Buy |
| 02/08/2023 | 19733.33% | Ladenburg Thalmann | → $119 | Reiterates | → Buy |
| 08/25/2022 | 983.33% | Ladenburg Thalmann | → $6.5 | Initiates Coverage On | → Buy |
| 08/15/2022 | — | Maxim Group | Downgrades | Buy → Hold | |
| 07/11/2022 | 316.67% | HC Wainwright & Co. | $3 → $2.5 | Maintains | Buy |
| 04/19/2022 | 400% | HC Wainwright & Co. | $5 → $3 | Maintains | Buy |
| 01/19/2022 | 316.67% | Maxim Group | → $2.5 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/13/2023 | 483.33% | HC Wainwright & Co. | → 3.5 美元 | 重申 | 購買 → 購買 |
| 11/06/2023 | 483.33% | HC Wainwright & Co. | $2 → 3.5 美元 | 維護 | 買 |
| 08/24/2023 | 233.33% | HC Wainwright & Co. | → 2 美元 | 重申 | 購買 → 購買 |
| 08/14/2023 | 233.33% | HC Wainwright & Co. | 7 美元 → 2 美元 | 維護 | 買 |
| 08/09/2023 | 233.33% | Maxim 集團 | 12 美元 → 2 美元 | 維護 | 買 |
| 05/12/2023 | 1066.67% | HC Wainwright & Co. | 6 美元 → 7 美元 | 維護 | 買 |
| 2023 年 3 月 24 日 | 900% | HC Wainwright & Co. | 10 美元 → 6 美元 | 重申 | → 購買 |
| 02/09/2023 | 1900% | Maxim 集團 | → 12 美元 | 升級 | 持有 → 買入 |
| 02/08/2023 | 1566.67% | HC Wainwright & Co. | → 10 美元 | 重申 | → 購買 |
| 02/08/2023 | 19733.33% | 拉登堡塔爾曼 | → 119 美元 | 重申 | → 購買 |
| 08/25/2022 | 983.33% | 拉登堡塔爾曼 | → 6.5 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 08/15/2022 | — | Maxim 集團 | 降級 | 買入 → 持有 | |
| 2022 年 11 月 7 日 | 316.67% | HC Wainwright & Co. | $3 → 2.5 美元 | 維護 | 買 |
| 04/19/2022 | 400% | HC Wainwright & Co. | 5 美元 → 3 美元 | 維護 | 買 |
| 2022 年 1 月 19 日 | 316.67% | Maxim 集團 | → 2.5 美元 | 啓動覆蓋範圍開啓 | → 購買 |
What is the target price for Kiora Pharmaceuticals (KPRX)?
Kiora Pharmicals（KPRX）的目標價格是多少？
The latest price target for Kiora Pharmaceuticals (NASDAQ: KPRX) was reported by HC Wainwright & Co. on November 13, 2023. The analyst firm set a price target for $3.50 expecting KPRX to rise to within 12 months (a possible 483.33% upside). 10 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 於2023年11月13日公佈了Kiora Pharmicals（納斯達克股票代碼：KPRX）的最新目標股價。該分析公司將目標股價定爲3.50美元，預計KPRX將在12個月內升至12個月內（可能上漲483.33％）。去年有10家分析公司公佈了評級。
What is the most recent analyst rating for Kiora Pharmaceuticals (KPRX)?
Kiora Pharmicals（KPRX）的最新分析師評級是多少？
The latest analyst rating for Kiora Pharmaceuticals (NASDAQ: KPRX) was provided by HC Wainwright & Co., and Kiora Pharmaceuticals reiterated their buy rating.
Kiora Pharmicals（納斯達克股票代碼：KPRX）的最新分析師評級由HC Wainwright & Co. 提供，Kiora Pharmicals重申了買入評級。
When is the next analyst rating going to be posted or updated for Kiora Pharmaceuticals (KPRX)?
Kiora Pharmicals（KPRX）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kiora Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kiora Pharmaceuticals was filed on November 13, 2023 so you should expect the next rating to be made available sometime around November 13, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Kiora Pharmicals的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。Kiora Pharmicals的最新評級是在2023年11月13日公佈的，因此您應該預計下一個評級將在2024年11月13日左右公佈。
Is the Analyst Rating Kiora Pharmaceuticals (KPRX) correct?
分析師對Kiora Pharmicals（KPRX）的評級正確嗎？
While ratings are subjective and will change, the latest Kiora Pharmaceuticals (KPRX) rating was a reiterated with a price target of $0.00 to $3.50. The current price Kiora Pharmaceuticals (KPRX) is trading at is $0.60, which is within the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但重申了最新的Kiora Pharmicals（KPRX）評級，目標股價爲0.00美元至3.50美元。Kiora Pharmicals（KPRX）目前的交易價格爲0.60美元，在分析師的預測區間內。
譯文內容由第三人軟體翻譯。